Eli Lilly is expanding its reach by partnering with the telehealth platform Ro to allow patients to order vials of its obesity medication Zepbound through Ro’s app. Previously, Lilly had only made these vials available to patients with prescriptions ordering directly through its online portal called LillyDirect. This partnership marks a significant development for Ro, which has been providing compounded copies of GLP-1 obesity drugs during shortages of branded treatments. Lilly has criticized the cheaper products made by compounding pharmacies and has even sent cease-and-desist letters to telehealth sites offering compounded products. The deal with Ro allows for broader access to Zepbound for patients.
Source link
Eli Lilly strikes Zepbound deal with Ro, amid questions on compounded GLP-1s
